LONDON (AFP) – Anglo-Swedish pharmaceuticals giant AstraZeneca yesterday agreed to buy French biotech specialist Amolyt Pharma for about USD1 billion, expanding further into the field of rare drugs.
“AstraZeneca… has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases,” it said in a statement.
The London-listed group added that the transaction would bolster its rare diseases division Alexion.
It will pay USD800 million upfront for the Lyon-based company, plus an additional payment of USD250 million payable after a specified regulatory milestone is reached.
“We enthusiastically welcome the proposed acquisition of Amolyt by AstraZeneca, an organisation that shares our dedication to delivering life-changing treatments to people living with rare diseases,” added Amolyt Pharma Chief Executive Thierry Abribat.
“This agreement offers the opportunity to meaningfully advance our pipeline therapies.”
AstraZeneca’s share price was up 0.1 per cent in early morning London trading following the news.
“The deal adds weight behind Astra’s rare disease division,” said lead equity analyst at stockbroker Hargreaves Lansdown Sophie Lund-Yates, noting that Amolyt is developing a treatment for an endocrine disorder which is in the final phase of clinical trials.
“This addition to the pipeline looks to be potentially lucrative.”
The transaction is expected to close by the end of the third quarter.
